BACKGROUND: Mutations in the PHF6 gene were recently described in patients with T-cell acute lymphoblastic leukemia and in those with acute myeloid leukemia. The present study was designed to determine the prevalence of PHF6 gene alterations in T-cell acute lymphoblastic leukemia. DESIGN AND METHODS: We analyzed the incidence and prognostic value of PHF6 mutations in 96 Chinese patients with T-cell acute lymphoblastic leukemia. PHF6 deletions were screened by real-time quantitative polymerase chain reaction and array-based comparative genomic hybridization. Patients were also investigated for NOTCH1, FBXW7, WT1, and JAK1 mutations together with CALM-AF10, SET-NUP214, and SIL-TAL1 gene rearrangements. RESULTS: PHF6 mutations were identified in 11/59 (18.6%) adult and 2/37 (5.4%) pediatric cases of T-cell acute lymphoblastic leukemia, these incidences being significantly lower than those recently reported. Although PHF6 is X-linked and mutations have been reported to occur almost exclusively in male patients, we found no sex difference in the incidences of PHF6 mutations in Chinese patients with T-cell acute lymphoblastic leukemia. PHF6 deletions were detected in 2/79 (2.5%) patients analyzed. NOTCH1 mutations, FBXW7 mutations, WT1 mutations, JAK1 mutations, SIL-TAL1 fusions, SET-NUP214 fusions and CALM-AF10 fusions were present in 44/96 (45.8%), 9/96 (9.4%), 4/96 (4.1%), 3/49 (6.1%), 9/48 (18.8%), 3/48 (6.3%) and 0/48 (0%) of patients, respectively. The molecular genetic markers most frequently associated with PHF6 mutations were NOTCH1 mutations (P=0.003), SET-NUP214 rearrangements (P=0.002), and JAK1 mutations (P=0.005). No differences in disease-free survival and overall survival between T-cell acute lymphoblastic leukemia patients with and without PHF6 mutations were observed in a short-term follow-up. CONCLUSIONS: Overall, these results indicate that, in T-cell acute lymphoblastic leukemia, PHF6 mutations are a recurrent genetic abnormality associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214.
BACKGROUND: Mutations in the PHF6 gene were recently described in patients with T-cell acute lymphoblastic leukemia and in those with acute myeloid leukemia. The present study was designed to determine the prevalence of PHF6 gene alterations in T-cell acute lymphoblastic leukemia. DESIGN AND METHODS: We analyzed the incidence and prognostic value of PHF6 mutations in 96 Chinese patients with T-cell acute lymphoblastic leukemia. PHF6 deletions were screened by real-time quantitative polymerase chain reaction and array-based comparative genomic hybridization. Patients were also investigated for NOTCH1, FBXW7, WT1, and JAK1 mutations together with CALM-AF10, SET-NUP214, and SIL-TAL1 gene rearrangements. RESULTS:PHF6 mutations were identified in 11/59 (18.6%) adult and 2/37 (5.4%) pediatric cases of T-cell acute lymphoblastic leukemia, these incidences being significantly lower than those recently reported. Although PHF6 is X-linked and mutations have been reported to occur almost exclusively in male patients, we found no sex difference in the incidences of PHF6 mutations in Chinese patients with T-cell acute lymphoblastic leukemia. PHF6 deletions were detected in 2/79 (2.5%) patients analyzed. NOTCH1 mutations, FBXW7 mutations, WT1 mutations, JAK1 mutations, SIL-TAL1 fusions, SET-NUP214 fusions and CALM-AF10 fusions were present in 44/96 (45.8%), 9/96 (9.4%), 4/96 (4.1%), 3/49 (6.1%), 9/48 (18.8%), 3/48 (6.3%) and 0/48 (0%) of patients, respectively. The molecular genetic markers most frequently associated with PHF6 mutations were NOTCH1 mutations (P=0.003), SET-NUP214 rearrangements (P=0.002), and JAK1 mutations (P=0.005). No differences in disease-free survival and overall survival between T-cell acute lymphoblastic leukemiapatients with and without PHF6 mutations were observed in a short-term follow-up. CONCLUSIONS: Overall, these results indicate that, in T-cell acute lymphoblastic leukemia, PHF6 mutations are a recurrent genetic abnormality associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214.
Authors: Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster Journal: Science Date: 2004-10-08 Impact factor: 47.728
Authors: Pieter Van Vlierberghe; Martine van Grotel; H Berna Beverloo; Charles Lee; Tryggvi Helgason; Jessica Buijs-Gladdines; Monique Passier; Elisabeth R van Wering; Anjo J P Veerman; Willem A Kamps; Jules P P Meijerink; Rob Pieters Journal: Blood Date: 2006-07-27 Impact factor: 22.113
Authors: Karen M Lower; Gillian Turner; Bronwyn A Kerr; Katherine D Mathews; Marie A Shaw; Agi K Gedeon; Susan Schelley; H Eugene Hoyme; Susan M White; Martin B Delatycki; Anne K Lampe; Jill Clayton-Smith; Helen Stewart; Conny M A van Ravenswaay; Bert B A de Vries; Barbara Cox; Markus Grompe; Shelley Ross; Paul Thomas; John C Mulley; Jozef Gécz Journal: Nat Genet Date: 2002-11-04 Impact factor: 38.330
Authors: F M Uckun; P S Gaynon; M G Sensel; J Nachman; M E Trigg; P G Steinherz; R Hutchinson; B C Bostrom; H N Sather; G H Reaman Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: M Kawamura; H Ohnishi; S X Guo; X M Sheng; M Minegishi; R Hanada; K Horibe; T Hongo; Y Kaneko; F Bessho; M Yanagisawa; T Sekiya; Y Hayashi Journal: Leuk Res Date: 1999-02 Impact factor: 3.156
Authors: Stephen Breit; Martin Stanulla; Thomas Flohr; Martin Schrappe; Wolf-Dieter Ludwig; Gabriele Tolle; Margit Happich; Martina U Muckenthaler; Andreas E Kulozik Journal: Blood Date: 2006-04-13 Impact factor: 22.113
Authors: Alena Malyukova; Takeaki Dohda; Natalie von der Lehr; Shahab Akhoondi; Shahab Akhondi; Martin Corcoran; Mats Heyman; Charles Spruck; Dan Grandér; Urban Lendahl; Olle Sangfelt Journal: Cancer Res Date: 2007-06-15 Impact factor: 12.701
Authors: Elisabeth Paietta; Adolfo A Ferrando; Donna Neuberg; John M Bennett; Janis Racevskis; Hillard Lazarus; Gordon Dewald; Jacob M Rowe; Peter H Wiernik; Martin S Tallman; A Thomas Look Journal: Blood Date: 2004-03-25 Impact factor: 22.113
Authors: P Van Vlierberghe; J Patel; O Abdel-Wahab; C Lobry; C V Hedvat; M Balbin; C Nicolas; A R Payer; H F Fernandez; M S Tallman; E Paietta; A Melnick; P Vandenberghe; F Speleman; I Aifantis; J Cools; R Levine; A Ferrando Journal: Leukemia Date: 2010-10-29 Impact factor: 11.528
Authors: Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal Journal: Blood Adv Date: 2018-12-11
Authors: Bartlomiej M Getta; Mikhail Roshal; Junting Zheng; Jae H Park; Eytan M Stein; Ross Levine; Esperanza B Papadopoulos; Ann A Jakubowski; Nancy A Kernan; Peter Steinherz; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Martin S Tallman; Brian C Shaffer Journal: Biol Blood Marrow Transplant Date: 2017-07-08 Impact factor: 5.742
Authors: Helen M McRae; Alexandra L Garnham; Yifang Hu; Matthew T Witkowski; Mark A Corbett; Mathew P Dixon; Rose E May; Bilal N Sheikh; William Chiang; Andrew J Kueh; Tan A Nguyen; Kevin Man; Renee Gloury; Brandon J Aubrey; Antonia Policheni; Ladina Di Rago; Warren S Alexander; Daniel H D Gray; Andreas Strasser; Edwin D Hawkins; Stephen Wilcox; Jozef Gécz; Axel Kallies; Matthew P McCormack; Gordon K Smyth; Anne K Voss; Tim Thomas Journal: Blood Date: 2019-02-12 Impact factor: 22.113
Authors: Zheng Ge; Min Li; Gang Zhao; Lichan Xiao; Yan Gu; Xilian Zhou; Michael D Yu; Jianyong Li; Sinisa Dovat; Chunhua Song Journal: Oncol Lett Date: 2016-08-10 Impact factor: 2.967
Authors: Evelien Mets; Gert Van Peer; Joni Van der Meulen; Michael Boice; Tom Taghon; Steven Goossens; Pieter Mestdagh; Yves Benoit; Barbara De Moerloose; Nadine Van Roy; Bruce Poppe; Jo Vandesompele; Hans-Guido Wendel; Pieter Van Vlierberghe; Frank Speleman; Pieter Rondou Journal: Haematologica Date: 2014-06-03 Impact factor: 9.941